EMA Recommends Extending Indications for Pembrolizumab and Adopted a New Pharmaceutical Form Along with a New Route of Administration By Ogkologos - October 3, 2025 293 0 Facebook Twitter Google+ Pinterest WhatsApp New indication concerns treatment of patients with resectable locally advanced head and neck squamous cell carcinoma Source RELATED ARTICLESMORE FROM AUTHOR ESMO Strengthens Global Oncology Collaboration Through its Growing Presence in the Asia-Pacific Pemigatinib Prolongs mPFS Over Chemotherapy in Patients with Advanced Cholangiocarcinoma with FGFR2 Fusions or Rearrangements FDA Approves Atezolizumab for Adjuvant Treatment of Muscle Invasive Bladder Cancer in Patients with Molecular Residual Disease MOST POPULAR High-Deductible Health Plans Linked to Delayed Diagnosis and Treatment of Breast... April 23, 2019 NEPA Plus Dexamethasone Provide Superior Chemotherapy-Induced Nausea and Vomiting Prevention Compared... November 18, 2025 The Appraisal – Scientific disruption: what is it, and do we... July 25, 2023 17 Old Fashioned Ways to Get Rid of Ants in Your... March 27, 2019 Load more HOT NEWS Former WNBA Player, Current Georgia Tech Coach Tasha Butts Diagnosed with... New on NCI’s Websites for March 2025 Similar Disease-Free Survival with Extended Intermittent or Continuous Treatment with Letrozole... EMA Recommends Extension of Therapeutic Indications for Acalabrutinib
